|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 168 USD | -1.31% |
|
+0.91% | +8.43% |
| 12/07 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
| 12/07 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
(Reuters) - AbbVie Inc on Tuesday raised its sales forecast of new drugs Skyrizi and Rinvoq for 2025 to more than $17.5 billion, compared with its previous outlook of more than $15 billion.
The revised forecast comes at a time when the company is facing revenue erosion of its biggest product Humira due to loss of exclusivity and entry of cheaper versions of the drug this year.
AbbVie also expects peak sales of Skyrizi and Rinvoq to exceed $21 billion in 2027.
The two immunology drugs are part of the company's long-term growth strategy following Humira's loss of exclusivity.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli and Shounak Dasgupta)
| 1st Jan change | Capi. | |
|---|---|---|
| +8.43% | 30TCr | |
| +63.05% | 86TCr | |
| +38.76% | 63TCr | |
| -4.78% | 36TCr | |
| +17.52% | 32TCr | |
| +13.68% | 24TCr | |
| +5.24% | 23TCr | |
| +16.53% | 23TCr | |
| +14.63% | 18TCr | |
| +1.08% | 16TCr |
ABBVIE INC. 
